Tomoo Matsutani

2.3k total citations
36 papers, 1.4k citations indexed

About

Tomoo Matsutani is a scholar working on Genetics, Molecular Biology and Epidemiology. According to data from OpenAlex, Tomoo Matsutani has authored 36 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Genetics, 15 papers in Molecular Biology and 8 papers in Epidemiology. Recurrent topics in Tomoo Matsutani's work include Glioma Diagnosis and Treatment (20 papers), Brain Metastases and Treatment (7 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Tomoo Matsutani is often cited by papers focused on Glioma Diagnosis and Treatment (20 papers), Brain Metastases and Treatment (7 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Tomoo Matsutani collaborates with scholars based in Japan, United States and France. Tomoo Matsutani's co-authors include Yasuo Iwadate, Paul S. Mischel, Naokatsu Saeki, Kenta Masui, Laurent Vergnes, Chann Lagadec, Karen Reue, Patrick D. Evers, Carmen Dekmezian and Erina Vlashi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Cell Metabolism and Cancer.

In The Last Decade

Tomoo Matsutani

33 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tomoo Matsutani Japan 17 856 525 431 298 192 36 1.4k
Qianghu Wang China 22 1.1k 1.3× 649 1.2× 407 0.9× 406 1.4× 122 0.6× 59 2.1k
Yanqing Ding China 18 800 0.9× 536 1.0× 195 0.5× 296 1.0× 114 0.6× 39 1.2k
Rolf Warta Germany 21 532 0.6× 324 0.6× 347 0.8× 335 1.1× 105 0.5× 53 1.2k
Gurpreet S. Kapoor United States 17 1.4k 1.6× 827 1.6× 847 2.0× 320 1.1× 111 0.6× 33 2.5k
Avadhut D. Joshi United States 15 709 0.8× 449 0.9× 436 1.0× 238 0.8× 59 0.3× 26 1.2k
Thomas Oellerich Germany 27 1.1k 1.3× 363 0.7× 274 0.6× 333 1.1× 143 0.7× 87 2.0k
Mariana Nacht United States 17 1.0k 1.2× 250 0.5× 235 0.5× 441 1.5× 94 0.5× 27 1.5k
Caroline Delmas France 22 794 0.9× 433 0.8× 343 0.8× 408 1.4× 41 0.2× 37 1.4k
Yuan Rong China 10 589 0.7× 368 0.7× 314 0.7× 155 0.5× 53 0.3× 15 1.1k
Esther Andion Spain 3 1.1k 1.3× 558 1.1× 957 2.2× 238 0.8× 127 0.7× 3 1.7k

Countries citing papers authored by Tomoo Matsutani

Since Specialization
Citations

This map shows the geographic impact of Tomoo Matsutani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomoo Matsutani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomoo Matsutani more than expected).

Fields of papers citing papers by Tomoo Matsutani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomoo Matsutani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomoo Matsutani. The network helps show where Tomoo Matsutani may publish in the future.

Co-authorship network of co-authors of Tomoo Matsutani

This figure shows the co-authorship network connecting the top 25 collaborators of Tomoo Matsutani. A scholar is included among the top collaborators of Tomoo Matsutani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomoo Matsutani. Tomoo Matsutani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Matsutani, Tomoo, et al.. (2023). 10203-ML-6 TIRABRUTINIB FOR PRIMARY CNS LYMPHOMA: A SINGLE INSTITUTE RETROSPECTIVE ANALYSIS. Neuro-Oncology Advances. 5(Supplement_5). v19–v20.
2.
Kubota, Masaaki, Yoichi Yoshida, Hao Wang, et al.. (2022). Serum anti‑TSTD2 antibody as a biomarker for atherosclerosis‑induced ischemic stroke and chronic kidney disease. PubMed. 3(1). 4–4. 2 indexed citations
3.
Higuchi, Yoshinori, Hajime Yokota, Yasuo Iwadate, et al.. (2022). The role of optimal cut-off diagnosis in 11C-methionine PET for differentiation of intracranial brain tumor from non-neoplastic lesions before treatment. Clinical Imaging. 92. 124–130. 3 indexed citations
4.
5.
6.
Kubota, Masaaki, Yoichi Yoshida, Eiichi Kobayashi, et al.. (2021). Serum anti-SERPINE1 antibody as a potential biomarker of acute cerebral infarction. Scientific Reports. 11(1). 21772–21772. 12 indexed citations
7.
Koyama‐Nasu, Ryo, Mariko Takami, Takahiro Aoki, et al.. (2020). CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy. Cancer Immunology Immunotherapy. 70(5). 1239–1254. 23 indexed citations
8.
Muto, Jun, Tomoo Matsutani, Ryosuke Matsuda, et al.. (2019). Temozolomide radiochemotherapy for high-grade glioma patients with hemodialysis: a case series of 7 patients. Neuro-Oncology Practice. 7(1). 111–117. 2 indexed citations
9.
Hirono, Seiichiro, et al.. (2018). Hammock Middle Cerebral Artery and Delayed Infarction in Lenticulostriate Artery After Staged Resection of Giant Insular Glioma. World Neurosurgery. 117. 80–83. 2 indexed citations
10.
Iwadate, Yasuo, Tomoo Matsutani, Seiichiro Hirono, et al.. (2018). Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade. Journal of Neuro-Oncology. 141(1). 205–211. 16 indexed citations
11.
Zhang, Xiaomin, Seiichiro Mine, Minoru Takemoto, et al.. (2017). Association of Serum Anti-Prolylcarboxypeptidase Antibody Marker with Atherosclerotic Diseases Accompanied by Hypertension. Journal of Molecular Biomarkers & Diagnosis. 8(6). 2 indexed citations
12.
Iwadate, Yasuo, Kazumasa Fukuda, Tomoo Matsutani, & Naokatsu Saeki. (2016). Intrinsic protective mechanisms of the neuron-glia network against glioma invasion. Journal of Clinical Neuroscience. 26. 19–25. 16 indexed citations
13.
Iwadate, Yasuo, et al.. (2016). Molecular imaging of 1p/19q deletion in oligodendroglial tumours with11C-methionine positron emission tomography. Journal of Neurology Neurosurgery & Psychiatry. 87(9). 1016–1021. 26 indexed citations
14.
Iwadate, Yasuo, et al.. (2015). IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy. Journal of Neuro-Oncology. 124(3). 493–500. 10 indexed citations
15.
Iwadate, Yasuo, Akiko Suganami, Shiro Ikegami, et al.. (2014). Non-deep-seated primary CNS lymphoma: therapeutic responses and a molecular signature. Journal of Neuro-Oncology. 117(2). 261–268. 15 indexed citations
16.
Sawai, Setsu, Shota Murata, Motoi Nishimura, et al.. (2014). Direct application of MALDI-TOF mass spectrometry to cerebrospinal fluid for rapid pathogen identification in a patient with bacterial meningitis. Clinica Chimica Acta. 435. 59–61. 71 indexed citations
17.
Masui, Kenta, Kazuhiro Tanaka, David Akhavan, et al.. (2013). mTOR Complex 2 Controls Glycolytic Metabolism in Glioblastoma through FoxO Acetylation and Upregulation of c-Myc. Cell Metabolism. 18(5). 726–739. 341 indexed citations
18.
Iwanami, Akio, Beatrice Gini, Ciro Zanca, et al.. (2013). PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proceedings of the National Academy of Sciences. 110(11). 4339–4344. 46 indexed citations
19.
Uchino, Yoshio, Kyosan Yoshikawa, Tomoo Matsutani, et al.. (2011). Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography. Journal of neurosurgery. 114(6). 1640–1647. 50 indexed citations
20.
Iwadate, Yasuo, et al.. (2011). Anaplastic oligodendroglial tumors harboring 1p/19q deletion can be successfully treated without radiotherapy.. PubMed. 31(12). 4475–9. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qianghu Wang Breakdown of academic impact, for papers by Yanqing Ding Breakdown of academic impact, for papers by Rolf Warta Breakdown of academic impact, for papers by Gurpreet S. Kapoor Breakdown of academic impact, for papers by Avadhut D. Joshi Breakdown of academic impact, for papers by Thomas Oellerich Breakdown of academic impact, for papers by Mariana Nacht Breakdown of academic impact, for papers by Caroline Delmas Breakdown of academic impact, for papers by Yuan Rong Breakdown of academic impact, for papers by Esther Andion
Rankless by CCL
2026